KRRO - NASDAQ
Korro Bio, Inc.
$11.08
+2.1%Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
At a Glance
Live SnapshotKorro Bio, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Moderate margins typical of competitive industries. Monitor for pricing pressure or rising costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Korro Bio, Inc. Income Statement
KRRO • NASDAQ
| Korro Bio, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||
6.4M | 2.3M | 0.0 | 0.0 | 14.1M | 37M | 28.9M | 0.0 | 0.0 | |
GROSS PROFIT | |||||||||
(4.3M) | (0.0) | (0.0) | (0.0) | (3.8M) | (1.6M) | (16.8M) | (654K) | (531K) | |
2.1M | 2.3M | 0.0 | 0.0 | 10.2M | 35.4M | 12.1M | -654K | -531K | |
OPERATING INCOME | |||||||||
(89.5M) | (94.2M) | (84.5M) | (59M) | (94.3M) | (63M) | (32.8M) | (18.3M) | (15.8M) | |
(28.2M) | (30.5M) | (36.5M) | (16.8M) | (34.9M) | (26.3M) | (14.5M) | (6.7M) | (4M) | |
(65.6M) | (63.6M) | (57.3M) | (42.2M) | (59.3M) | (36.7M) | (18.3M) | (11.6M) | (11.8M) | |
-87.3M | -91.9M | -84.5M | -59M | -84M | -27.6M | -20.7M | -18.9M | -16.3M | |
PRE-TAX INCOME | |||||||||
(0.0) | (0.0) | (0.0) | (118K) | (764K) | (0.0) | (0.0) | (106K) | (174K) | |
0.0 | 0.0 | 0.0 | 829K | -367K | 994K | 0.0 | 0.0 | 0.0 | |
-4.3M | (0.0) | -9.3M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-29.3M | 8.5M | 3.4M | 976K | -640K | 1.1M | 1.9M | -224K | -3.9M | |
-116.6M | -83.4M | -81.1M | -58M | -84.7M | -26.5M | -18.7M | -19.2M | -20.2M | |
NET INCOME | |||||||||
(637K) | (141K) | (27K) | (10K) | (15K) | (35K) | (0.0) | (0.0) | (0.0) | |
-117.3M | -83.6M | -81.2M | -58M | -84.7M | -26.5M | -18.7M | -19.2M | -20.2M |
SEC Filings
KRRO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 19, 2026 | May 19, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 16, 2026 | June 10, 2026 | 2026 | |
S-3 S-3 N/A | March 13, 2026 | March 13, 2026 | ||
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 27, 2026 | January 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 15, 2026 | January 15, 2026 | 2026 |
Related Guides
Continue your KRRO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.